Axon Stock Surges 14% on AI Pivot
Axon Enterprise's stock soared 14% after its Q4 earnings beat expectations with a 38.5% year-over-year revenue jump. Management successfully tied the growth directly to the company's pivot into generative AI. The market's strong positive reaction underscores investor appetite for clear narratives that link AI investment to top- and bottom-line results.
The fourth-quarter earnings beat was significant, with adjusted earnings per share hitting $2.15, crushing analyst estimates of around $1.67. Revenue reached $797 million for the quarter, well above the consensus estimate of approximately $755 million. At the core of the AI strategy is "Draft One," a generative AI tool that transcribes body camera audio and creates draft police reports in seconds. This software is a key driver of high-margin subscriptions, with one estimate suggesting it saves officers 67% of the time they would typically spend on paperwork. CEO Rick Smith framed the AI shift as a pivotal moment, stating, "nobody should be more aggressive or more thoughtful on AI than Axon." AI-related products, including the "Axon Assistant" voice tool, accounted for about $750 million in bookings last year. The company issued a bullish forecast for 2026, projecting revenue growth between 27% and 30%. Looking further ahead, management established a new long-term target of achieving $6 billion in annual revenue by 2028. Underscoring the transition to a software-as-a-service model, Axon's total future contracted bookings surged 43% to a record $14.4 billion. This provides significant visibility into future earnings, with high-margin annual recurring revenue already up 35% to $1.3 billion. While AI dominated the narrative, strong demand for new hardware was also a critical growth driver. Sales of the new TASER 10 weapon and the Axon Body 4 camera, which offers bi-directional voice communication, significantly contributed to the quarter's success. Following the report, the consensus analyst rating is a "Strong Buy." However, some firms, including RBC Capital and Morgan Stanley, trimmed their price targets after the stock's sharp rally, despite maintaining their "Overweight" or "Outperform" ratings.
